Bulltick Wealth Management LLC Raises Stock Position in Pfizer Inc. (NYSE:PFE)

Key Points

• Bulltick Wealth Management LLC increased its holdings in Pfizer by 62.6% during the first quarter, now owning 139,955 shares valued at approximately $3.546 million.
• Pfizer reported $0.78 earnings per share for the most recent quarter, exceeding expectations, with revenues of $14.65 billion and a net margin of 16.84%.
• The company declared a quarterly dividend of $0.43 per share, resulting in an annualized dividend of $1.72 and a yield of 7.0%.

Bulltick Wealth Management LLC raised its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 62.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 139,955 shares of the biopharmaceutical company's stock after buying an additional 53,894 shares during the period. Bulltick Wealth Management LLC's holdings in Pfizer were worth $3,546,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Clarity Asset Management Inc. bought a new position in shares of Pfizer during the fourth quarter valued at about $27,000. Gould Capital LLC raised its stake in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 493 shares during the last quarter. North Capital Inc. bought a new position in shares of Pfizer during the first quarter valued at about $28,000. Bayforest Capital Ltd bought a new position in shares of Pfizer during the first quarter valued at about $28,000. Finally, Bernard Wealth Management Corp. bought a new position in shares of Pfizer during the fourth quarter valued at about $30,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Up 0.2%

Shares of NYSE:PFE traded up $0.06 during trading on Tuesday, reaching $24.64. 34,400,469 shares of the stock traded hands, compared to its average volume of 47,175,628. The stock has a 50-day moving average of $24.49 and a two-hundred day moving average of $24.47. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The stock has a market cap of $140.06 billion, a P/E ratio of 13.10, a price-to-earnings-growth ratio of 0.88 and a beta of 0.52.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. During the same quarter in the prior year, the company posted $0.60 earnings per share. The business's revenue for the quarter was up 10.3% on a year-over-year basis. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.0%. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

Wall Street Analyst Weigh In

PFE has been the subject of several recent analyst reports. TD Cowen lowered their price objective on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a research note on Tuesday, April 22nd. Wolfe Research raised their price objective on shares of Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a report on Wednesday, April 30th. The Goldman Sachs Group raised their price objective on shares of Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Citigroup raised their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Finally, Cantor Fitzgerald assumed coverage on shares of Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.